Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4375 injection in combination therapy for advanced solid tumors
CTR20254944Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jan 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-4375 in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Primary endpoints: DLT (dose-limiting toxicity), RP2D (recommended phase 2 dose) and 3 more. Started Jan 2026; status: active.
02
Drugs
SHR-4375
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254944.